We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+14.39%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.85B
AUM Growth
+$177M
Cap. Flow
-$53.9M
Cap. Flow %
-1.89%
Top 10 Hldgs %
28.19%
Holding
216
New
12
Increased
42
Reduced
44
Closed
16

Top Buys

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$46M
2
DHR icon
Danaher
DHR
+$34.4M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$30.2M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$22.3M
5
DXCM icon
DexCom
DXCM
+$20M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$44.2M
2
MRK icon
Merck
MRK
+$39.7M
3
PFE icon
Pfizer
PFE
+$39.7M
4
ABBV icon
AbbVie
ABBV
+$24.5M
5
CNC icon
Centene
CNC
+$23.8M

Sector Composition

Rank Sector Weight
1 Healthcare 95.34%
2 Real Estate 2.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OHI icon
76
Omega Healthcare
OHI
$14.7B
$11.1M 0.39%
306,433
– –
IONS icon
77
Ionis Pharmaceuticals
IONS
$9.06B
$10.9M 0.38%
193,201
– –
GRTX
78
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$10.7M 0.37%
1,041,845
– –
GMAB icon
79
Genmab
GMAB
$17.6B
$10.5M 0.37%
258,672
+73,893
+40% +$2.76M
VTR icon
80
Ventas
VTR
$46.6B
$10.2M 0.36%
208,108
– –
ARWR icon
81
Arrowhead Research
ARWR
$12.1B
$10.2M 0.36%
132,886
+58,700
+79% +$3.75M
UTHR icon
82
United Therapeutics
UTHR
$21.9B
$9.64M 0.34%
63,513
– –
FOLD
83
DELISTED
Amicus Therapeutics
FOLD
$9.37M 0.33%
405,626
– –
ZTS icon
84
Zoetis
ZTS
$32.3B
$9.35M 0.33%
56,521
– –
MPT
85
Medical Properties Trust
MPT
$2.75B
$8.97M 0.32%
411,743
– –
CCXI
86
DELISTED
ChemoCentryx, Inc.
CCXI
$8.94M 0.31%
144,447
– –
KURA icon
87
Kura Oncology
KURA
$841M
$8.93M 0.31%
273,463
+214,124
+361% +$7.52M
SBRA icon
88
Sabra Healthcare REIT
SBRA
$5.2B
$8.87M 0.31%
510,660
– –
BSX icon
89
Boston Scientific
BSX
$70.2B
$8.85M 0.31%
246,089
-495,207
-67% -$17.8M
DOC
90
DELISTED
PHYSICIANS REALTY TRUST
DOC
$8.82M 0.31%
495,733
– –
KRTX
91
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$8.66M 0.3%
85,236
+43,409
+104% +$4.02M
NVAX icon
92
Novavax
NVAX
$1.22B
$8.54M 0.3%
76,585
+65,062
+565% +$6.92M
MOH icon
93
Molina Healthcare
MOH
$10.2B
$8.46M 0.3%
39,769
-2,900
-7% -$599K
EXAS
94
DELISTED
Exact Sciences
EXAS
$8.41M 0.3%
63,502
+48,352
+319% +$5.85M
INCY icon
95
Incyte
INCY
$24B
$8.11M 0.29%
93,257
-59,348
-39% -$5.13M
TBPH icon
96
Theravance Biopharma
TBPH
$874M
$8.11M 0.28%
456,296
+157,826
+53% +$2.83M
ONC
97
BeOne Medicines Ltd
ONC
$32.6B
$7.31M 0.26%
28,280
– –
KYNB
98
Kyntra Bio
KYNB
$27.4M
$7.21M 0.25%
7,771
– –
ACH
99
Accendra Health
ACH
$261M
$7.2M 0.25%
+266,023
New +$6.84M
LTC
100
LTC Properties
LTC
$1.99B
$7.09M 0.25%
182,293
– –
2 3
4
5 6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Tekla Capital Management held 216 positions worth $2.85B, up 6.6% from $2.67B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Tekla Capital Management's Q4 2020 filing shows 12 new, 42 increased, 44 reduced and 16 closed positions. Its largest new stake was Teladoc Health: 56,520 shares worth $11.3M. The largest sale was Amgen, an estimated $44.2M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q4 2020 buy was Teladoc Health: 56,520 shares worth $11.3M.
  • Tekla Capital Management added most to Thermo Fisher Scientific in Q4 2020, an estimated $46M increase.
  • Tekla Capital Management's biggest Q4 2020 reduction was Amgen, cutting an estimated $44.2M.
  • Tekla Capital Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $19M.
  • Tekla Capital Management's ten largest holdings make up 28% of its $2.85B portfolio in Q4 2020.
  • Tekla Capital Management opened 12 new positions and closed 16 in Q4 2020.
  • Tekla Capital Management's portfolio value rose 6.6% quarter-over-quarter to $2.85B.

Based on Tekla Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.